264 related articles for article (PubMed ID: 28968302)
1. NAMS 3rd Utian Translational Science Symposium, October 2016, Orlando, Florida A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?
The North American Menopause Society (NAMS)
Menopause; 2017 Nov; 24(11):1221-1235. PubMed ID: 28968302
[TBL] [Abstract][Full Text] [Related]
2. The 2017 hormone therapy position statement of The North American Menopause Society.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
[TBL] [Abstract][Full Text] [Related]
3. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
5. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
[TBL] [Abstract][Full Text] [Related]
6. The 2022 hormone therapy position statement of The North American Menopause Society.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2022 Jul; 29(7):767-794. PubMed ID: 35797481
[TBL] [Abstract][Full Text] [Related]
7. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2010 Mar; 17(2):242-55. PubMed ID: 20154637
[TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
10. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR; Monteleone P; Giannini A; Simoncini T
Hum Reprod Update; 2021 Oct; 27(6):1115-1150. PubMed ID: 34432008
[TBL] [Abstract][Full Text] [Related]
11. Safety and benefit considerations for menopausal hormone therapy.
Pickar JH; Archer DF; Kagan R; Pinkerton JV; Taylor HS
Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
[TBL] [Abstract][Full Text] [Related]
12. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
13. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2003; 10(2):113-32. PubMed ID: 12627037
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(2):168-82. PubMed ID: 17259911
[TBL] [Abstract][Full Text] [Related]
15. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies.
Carrasquilla GD; Frumento P; Berglund A; Borgfeldt C; Bottai M; Chiavenna C; Eliasson M; Engström G; Hallmans G; Jansson JH; Magnusson PK; Nilsson PM; Pedersen NL; Wolk A; Leander K
PLoS Med; 2017 Nov; 14(11):e1002445. PubMed ID: 29149179
[TBL] [Abstract][Full Text] [Related]
16. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
Du Y; Scheidt-Nave C; Schaffrath Rosario A; Ellert U; Dören M; Knopf H
Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
[TBL] [Abstract][Full Text] [Related]
17. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
[TBL] [Abstract][Full Text] [Related]
18. [Basic principles of hormone replacement therapy in the postmenopause].
Dören M
Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
[TBL] [Abstract][Full Text] [Related]
19. The 2012 hormone therapy position statement of: The North American Menopause Society.
North American Menopause Society
Menopause; 2012 Mar; 19(3):257-71. PubMed ID: 22367731
[TBL] [Abstract][Full Text] [Related]
20. Estrogen plus progestin therapy: the cardiovascular risks exceed the benefits.
Penckofer SM; Hackbarth D; Schwertz DW
J Cardiovasc Nurs; 2003; 18(5):347-55. PubMed ID: 14680337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
